Back to Search
Start Over
HIV Pre-Exposure Prophylaxis Medication for Adolescents and Young Adults: A Position Paper of the Society for Adolescent Health and Medicine.
- Source :
-
The Journal of adolescent health : official publication of the Society for Adolescent Medicine [J Adolesc Health] 2018 Oct; Vol. 63 (4), pp. 513-516. - Publication Year :
- 2018
-
Abstract
- Pre-exposure prophylaxis (PrEP) is a biomedical prevention intervention that has demonstrated high efficacy in reducing human immunodeficiency virus (HIV) transmission. While an increasing number of jurisdictions have endorsed the use of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for PrEP, access to PrEP varies widely. Adolescents and young adults (AYAs), especially those at high risk of HIV acquisition, such as young gay, bisexual, and other men having sex with men (YGBMSM) and individuals living in countries where HIV is endemic, face multiple barriers that limit their access to PrEP. This position paper provides context and recommendations for the promotion and use of PrEP among AYAs.<br /> (Copyright © 2018. Published by Elsevier Inc.)
- Subjects :
- Adolescent
Adult
Anti-HIV Agents therapeutic use
Emtricitabine administration & dosage
Female
Humans
Male
Medication Adherence
Tenofovir administration & dosage
Young Adult
Adolescent Health
HIV Infections prevention & control
Health Services Accessibility
Pre-Exposure Prophylaxis
Sexual and Gender Minorities
Subjects
Details
- Language :
- English
- ISSN :
- 1879-1972
- Volume :
- 63
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- The Journal of adolescent health : official publication of the Society for Adolescent Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 30286903
- Full Text :
- https://doi.org/10.1016/j.jadohealth.2018.07.021